COMP <GO>
CORT vs MDGL // ALTMAN Z-SCORE & DEBT/EQUITY
Corcept Therapeutics Incorporated (NASDAQ) VS. Madrigal Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: CORT 6
— MDGL 5
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: CORT
LAST: $80.46 (-0.81%) • MKT CAP: $8.77B
balance-sheet
26.00
LAST: $431.16 (+0.19%) • MKT CAP: $9.94B
balance-sheet
7.65
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CORT VS. MDGL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CORT | MDGL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.80% | -29.70% | +34.50 | CORT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.53% | -1.91% | +3.44 | CORT | /fcf-yield <GO> |
| Operating Margin | 5.90% | -31.30% | +37.20 | CORT | /operating-margins <GO> |
| Net Profit Margin | 13.10% | -30.10% | +43.20 | CORT | /net-margins <GO> |
| Revenue Growth (YoY) | 12.80% | 180.00% | -167.20 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 7.65 | +18.35 | CORT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | CORT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.6 | 30.1 | -2.50 | MDGL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.88 | 1.08 | -0.20 | MDGL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.3x | 24.0x | +54.30 | MDGL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.77B | $9.94B | -$1.17B | MDGL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CORT REV | MDGL REV | CORT GROSS % | MDGL GROSS % | CORT FCF | MDGL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | $958.4M | 98.3% | — | $141.8M | -$190.0M |
| FY 2024 | $675.0M | $180.1M | 98.4% | 96.5% | $196.1M | -$457.0M |
| FY 2023 | $482.4M | $1.07B | — | — | $105.0M | -$324.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CORT // BETA 0.88
MDGL // BETA 1.08